Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL1574049 | 0.86 | LMNA (0.55) | LMNATHRB | |
| Di(Hydroxyethyl)Ether SCHEMBL10711395 | 0.86 | LMNA (0.60) | LMNAALDH1A1MEN1KMT2ATHRB | |
| Triethylene Glycol SCHEMBL21903477 | 0.84 | LMNA (0.52) | LMNAALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL5275388 | 0.84 | LMNA (0.52) | LMNAALDH1A1MEN1KMT2ATHRB | |
| Diethylene Glycol Monoethyl Ether SCHEMBL2952919 | 0.84 | ALDH1A1 (0.61) | LMNAALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL126615 | 0.82 | LMNA (0.67) | LMNATHRB | |
| Triethylene Glycol SCHEMBL3199626 | 0.80 | LMNA (0.39) | LMNAALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL6135761 | 0.80 | LMNA (0.63) | LMNATHRB | |
| Ethylene SCHEMBL10332980 | 0.80 | LMNA (0.63) | LMNATHRB | |
| SCHEMBL17764548 | 0.79 | TSHR (0.65) | LMNAALDH1A1MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048151-A1 | PEG-Poly(Ortho Ester) Graft Copolymers and Pharmaceutical Compositions | A.P. PHARMA, INC. | 2009-02-19 | — | — | US | disclosed |
| US-7456213-B2 | PEG-poly(ortho ester) graft copolymers and pharmaceutical compositions | A.P. PHARMA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1865989-A2 | PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS | AP Pharma, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060235083-A1 | PEG-poly(ortho ester) graft copolymers and pharmaceutical compositions | HERON THERAPEUTICS, INC. (F/K/A A.P. PHARMA, INC.) | 2006-10-19 | — | — | US | disclosed |
| WO-2006105148-A2 | PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS | AP PHARMA, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048151-A1 | PEG-Poly(Ortho Ester) Graft Copolymers and Pharmaceutical Compositions | CEL, PTPRG, OGFR | LMNA 4686/4885ALDH1A1 4021/4885MEN1 4436/4885 |
| US-20060235083-A1 | PEG-poly(ortho ester) graft copolymers and pharmaceutical compositions | CEL, PTPRG, OGFR | LMNA 4686/4885ALDH1A1 4021/4885MEN1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.